CETUXIMAB

UNII:	PQX0D8J21J
Formula:
Preferred Substance Name:	CETUXIMAB

205923-56-4
ABP-494
C225
C-225
CETUXIMAB (GENETICAL RECOMBINATION)
CETUXIMAB (GENETICAL RECOMBINATION) [JAN]
CETUXIMAB [EMA EPAR]
CETUXIMAB [HSDB]
CETUXIMAB [INN]
CETUXIMAB [JAN]
CETUXIMAB [MART.]
CETUXIMAB [MI]
CETUXIMAB [PURPLE BOOK CDER]
CETUXIMAB [USAN]
CETUXIMAB [VANDF]
CETUXIMAB [WHO-DD]
CETUXIMAB BETA
CETUXIMAB BETA [INN]
CETUXIMAB BIOSIMILAR (ABP-494)
CETUXIMAB BIOSIMILAR (SHANGHAI ZHANGJIANG)
CMAB009
CMAB-009
CMAB-009 (BIOSIMILAR OF CETUXIMAB)
ERBITUX
EXTRACELLULAR DOMAIN HUMAN EGFR BINDING RECOMBINANT, HUMAN/MOUSE CHIMERIC MONOCLONAL ANTIBODY
FV REGIONS OF MURINE ANTI-EGFR ANTIBODY WITH HUMAN IGG1 HEAVY AND KAPPA LIGHT CHAIN CONSTANT REGIONS, MW 152000
IMC-225
IMCC225
IMCC-225
IMC-C225
IMMUNOGLOBULIN G1, ANTI-(HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR) (HUMAN-MOUSE MONOCLONAL C225 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL C225 .KAPPA.-CHAIN, DIMER
MOAB C225

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

CETUXIMAB

Synonyms and Mappings

Resources